Plant Medicine Retreat FAQ

Ayahuasca contains DMT which is a Schedule I substance in the US and controlled in most Western countries. However, in Peru, Costa Rica, and Brazil, ayahuasca use is legally protected as a cultural or religious practice, and commercial retreat operations exist in a broadly accepted legal framework. In the Netherlands, ayahuasca is legal. Jamaica has no ayahuasca prohibition. For most Western nationals, participating in an ayahuasca retreat in Peru or Costa Rica involves no legal risk — but bringing any substance home is a serious offence.

Yes — Australia became the first country to formally approve psilocybin and MDMA as medicines for psychiatric conditions. Since July 2023, authorised psychiatrists can prescribe psilocybin for treatment-resistant depression and MDMA for PTSD. This is a landmark global policy change. Access requires referral from a GP or psychologist to an authorised prescriber, and treatment occurs in clinical settings. It is not widely available yet — but the framework exists and is expanding.

No — this is a serious contraindication. Ayahuasca contains MAO inhibitors (from the Banisteriopsis caapi vine) that prevent the breakdown of serotonin. Combining this with SSRIs, SNRIs, or other serotonergic medications creates a serious risk of serotonin syndrome — a potentially life-threatening condition. If you are currently taking antidepressants and wish to explore ayahuasca, you must speak with your prescribing physician about a carefully managed tapering protocol — typically 2–4 weeks minimum — before any ceremony. Never stop psychiatric medication abruptly.

Integration is the process of making sense of and applying the insights, emotions, or experiences that arise during a plant medicine session. The ceremony or session itself is 10–20% of the therapeutic work — the other 80–90% happens in the weeks and months of reflection, conversation, and behaviour change that follow. Reputable retreats include multiple integration sessions: circles immediately after the ceremony, follow-up calls at 2 weeks and 1 month, and connection to ongoing integration therapists or circles. Retreats without integration support are missing the most important part.

For properly screened participants with proper facilitator support — yes. For people with undisclosed contraindications (family history of psychosis, current lithium use, active SSRI use with ayahuasca) — no. The evidence base for psilocybin-assisted therapy specifically shows it is one of the safest substances when administered in controlled settings: no physical toxicity, no addiction liability, no overdose threshold. The risks are psychological (difficult experiences, anxiety, temporary disorientation) and interaction-based (drug interactions). Proper screening eliminates most of these risks.

Costs vary significantly by medicine and location: Oregon psilocybin licensed sessions: $1,500–$4,500 per session. Jamaica psilocybin retreats: $3,000–$6,000 for week-long programmes. Costa Rica ayahuasca retreats: $2,500–$8,000 per week. Netherlands psilocybin retreats: $2,500–$6,000. Luxury retreat centres (Rythmia, Synthesis premium programmes): $5,000–$12,000+. Ketamine therapy domestically: $400–$800 per infusion, typically 6 sessions. The range reflects both medicine type and the quality of the surrounding programme — preparation, integration, and setting.

Apply this five-point checklist: (1) Verify legal operating status in their jurisdiction. (2) Confirm facilitator credentials — Oregon and Colorado require licensed facilitators you can look up. (3) Review their screening protocol — do they ask about medications and psychiatric history? (4) Confirm integration support is included, not an optional add-on. (5) Look for real independent reviews on platforms not controlled by the retreat itself. Any retreat that does not have clear answers to all five is not ready for your booking.